Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€8.95

€8.95

-4.380%
-0.41
-4.380%
-

-

 
07.05.21 / Frankfurt WKN: A2ANGZ / Name: Gensight / Stock / Biotechnology & Medical Research / Micro Cap /
Latest predictions
-
02.09.20
-
12.01.20
buy
-
12.01.20
buy
Your prediction

Gensight Biologics SA Stock

Gensight Biologics SA took a tumble today and lost -€0.410 (-4.380%).
Based on 2 Buy predictions and 1 Sell predictions the sentiment towards Gensight Biologics SA is rather balanced.

Pros and Cons of Gensight Biologics SA in the next few years

Pros
?
Brand
?
Shareholder structure
?
Worthwhile Investment for the next years
Cons
?
Market Position
?
Growth compared to competition
?
Conscious of the environment
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of Gensight Biologics SA vs. its peers

Security Change (%) 1w 1m 1y YTD 3y 5y
Gensight Biologics SA -4.380% 4.556% 21.603% 200.336% 33.185% 198.333% -
Celsion Corp. -5.490% -11.340% -28.926% -23.214% 49.565% -55.897% -95.140%
CEL-SCI Corp. -0.300% -26.682% 9.732% 37.337% 68.661% 747.150% 34.568%
Aptevo Therapeutics Inc. -5.320% -12.250% -16.429% 314.270% -28.500% -61.803% -

Comments

Prediction Buy
Perf. (%) 143.05%
Target price 1.520
Change
Ends at 15.01.20

Buy closed
Show more

Buy Gensight Biologics SA
Show more

Prediction Buy
Perf. (%) 143.05%
Target price 1.520
Change
Ends at 15.01.20

Buy with target price 1.52
Show more

Other discussions about Gensight Biologics SA Stock

New thread Forum

News

GenSight Biologics Announces Publication of Results from the REALITY LHON Natural History Study in the Journal Eye: https://mms.businesswire.com/media/20210502005042/en/875371/5/Figure_1.jpg
GenSight Biologics Announces Publication of Results from the REALITY LHON Natural History Study in the Journal Eye


Regulatory News:


This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210502005042/en/



Figure 1. Evolution of BCVA in ND4-LHON patients


GenSight Biologics Reports Cash Position as of March 31, 2021 and Provides Operational Update: https://mms.businesswire.com/media/20191208005050/en/761225/5/Logo+Centre+Hospitalier+XV-XX.jpg
GenSight Biologics Reports Cash Position as of March 31, 2021 and Provides Operational Update


Regulatory News:



GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies

GenSight Biologics Reports Full Year 2020 Financial Results and provides an Outlook on 2021: https://mms.businesswire.com/media/20191208005050/en/761225/5/Logo+Centre+Hospitalier+XV-XX.jpg
GenSight Biologics Reports Full Year 2020 Financial Results and provides an Outlook on 2021


Regulatory News:



GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on discovering and developing innovative gene therapies for